Dietary aspartyl-phenylalanine-1-methyl ester delays osteoarthritis and prevents associated bone loss in STR/ORT mice

Rheumatology

Volumn 50, Issue 7, 2011, Pages 1244-1249

  Manion, Carl V ^a   Hochgeschwender, Ute ^a   Edmundson, Allen B ^a   Hugli, Tony E ^b   Gabaglia, Claudia R ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

Author keywords

Asp Phe OMe; Aspartame; Bone density; Dipeptide aspartyl phenylalanine 1 methyl ester; Gait; Mice; Muscle mass; Osteoarthritis

Indexed keywords

ASPARTAME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MASS; CORTICAL BONE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; FOOD INTAKE; GAIT; LIFESPAN; MALE; MOUSE; MOVEMENT (PHYSIOLOGY); MUSCLE MASS; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; WEANING; WEIGHT GAIN;

ANALYSIS OF VARIANCE; ANIMALS; ASPARTAME; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; LINEAR MODELS; LOCOMOTION; MALE; MICE; MICE, INBRED STRAINS; MUSCLE, SKELETAL; OSTEOARTHRITIS; OSTEOPOROSIS; RANDOM ALLOCATION; REFERENCE VALUES;

EID: 79959420445     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker089     Document Type: Article

References (15)

1. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007;213:626-34.
2. Walton M. Degenerative joint disease in the mouse knee; radiological and morphological observations. J Pathol 1977;123:97-107.
3. Evans RG, Collins C, Miller P, Ponsford FM, Elson CJ. Radiological scoring of osteoarthritis progression in STR/ORT mice. Osteoarthr Cartil 1994;2:103-9.
4. Anderson-MacKenzie JM, Billingham ME, Bailey AJ. Collagen remodeling in the anterior cruciate ligament associated with developing spontaneous murine osteoarthritis. Biochem Biophys Res Commun 1999;258: 763-7.
5. Butchko HH, Stargel WW, Comer CP et al. Aspartame: review of safety. Regul Toxicol Pharmacol 2002;35:S1-93.
6. Leon AS, Hunninghake DB, Bell C, Rassin DK, Tephly TR. Safety of long-term large doses of aspartame. Arch Intern Med 1989;149:2318-24.
7. Renwick AG, Nordmann H. First European conference on aspartame: putting safety and benefits into perspective. Synopsis of presentations and conclusions. Food Chem Toxicol 2007;45:1308-13.
8. Edmundson AB, Manion CV. Treatment of osteoarthritis with aspartame. Clin Pharmacol Ther 1998;63: 580-93.
9. Sharma S, Jain NK, Kulkarni SK. Possible analgesic and anti-inflammatory interactions of aspartame with opioids and NSAIDs. Indian J Exp Biol 2005;43: 498-502.
10. LaBuda CJ, Fuchs PN. A comparison of chronic aspartame exposure to aspirin on inflammation, hyperalgesia and open field activity following carrageenan-induced monoarthritis. Life Sci 2001;69: 443-54.
11. Lin CH, Tallaksen-Greene S, Chien WM et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 2001;10:137-44.
12. Matsuzawa Y, O'Hara Y. Tissue distribution of orally administered isotopically labelled aspartame in the rat. In: Stegink Lewis D., Filer L.J., eds. Aspartame physiology and biochemistry. NewYork: Marcel Dekker, Inc., 1984:161-99.
13. Burr DB. Anatomy and physiology of the mineralized tissues: role in the pathogenesis of osteoarthrosis. Osteoarthr Cartil 2004;12(Suppl. A): S20-30.
14. Turner RT, Lotinun S, Hefferan TE, Morey-Holton E. Disuse in adult male rats attenuates the bone anabolic response to a therapeutic dose of parathyroid hormone. J Appl Physiol 2006;101:881-6.
15. Li B, Aspden RM. Composition and mechanical properties of cancellous bone from the femoral head of patients with osteoporosis or osteoarthritis. J Bone Miner Res 1997;12: 641-51.